Evidence map›Paper›PMID 37213314›Full record

ReviewAmerican journal of cardiovascular disease2023

An exploration of the early discharge approach for low-risk STEMI patients following primary percutaneous coronary intervention.

Nicole Broughton, Katrina Comer, Oliver Casey-Gillman, Lizze Moore, Sotiris Antoniou, Riyaz Patel, Sadeer Fhadil, Paul Wright, Muhiddin Ozkor, Oliver Guttmann and 7 more

Open access · greenAbstract readReview
In one paragraph

Review in American journal of cardiovascular disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Nicole BroughtonCentre for Cardiovascular Medicine and Devices, Willian Harvey Research Institute, Queen Mary University of London London EC1A 7BE, UK.
Katrina ComerDepartment of Cardiology, Barts Heart Centre, Barts Health NHS Trust London EC1A 7BE, UK.
Oliver Casey-GillmanDepartment of Cardiology, Barts Heart Centre, Barts Health NHS Trust London EC1A 7BE, UK.
Lizze MooreDepartment of Cardiology, Barts Heart Centre, Barts Health NHS Trust London EC1A 7BE, UK.
Sotiris AntoniouDepartment of Pharmacy, Barts Heart Centre, Barts Health NHS Trust London EC1A 7BE, UK.
Riyaz PatelDepartment of Cardiology, Barts Heart Centre, Barts Health NHS Trust London EC1A 7BE, UK.
Sadeer FhadilDepartment of Pharmacy, Barts Heart Centre, Barts Health NHS Trust London EC1A 7BE, UK.
Paul WrightDepartment of Pharmacy, Barts Heart Centre, Barts Health NHS Trust London EC1A 7BE, UK.
Muhiddin OzkorBarts Interventional Group, Barts Heart Centre, Barts Health NHS Trust London EC1A 7BE, UK.
Oliver GuttmannBarts Interventional Group, Barts Heart Centre, Barts Health NHS Trust London EC1A 7BE, UK.
Andreas BaumbachCentre for Cardiovascular Medicine and Devices, Willian Harvey Research Institute, Queen Mary University of London London EC1A 7BE, UK.
Andrew WraggBarts Interventional Group, Barts Heart Centre, Barts Health NHS Trust London EC1A 7BE, UK.
Ajay J JainBarts Interventional Group, Barts Heart Centre, Barts Health NHS Trust London EC1A 7BE, UK.
Fizzah ChoudryCentre for Cardiovascular Medicine and Devices, Willian Harvey Research Institute, Queen Mary University of London London EC1A 7BE, UK.
Anthony MathurCentre for Cardiovascular Medicine and Devices, Willian Harvey Research Institute, Queen Mary University of London London EC1A 7BE, UK.
Krishnaraj S RathodCentre for Cardiovascular Medicine and Devices, Willian Harvey Research Institute, Queen Mary University of London London EC1A 7BE, UK.
Daniel A JonesCentre for Cardiovascular Medicine and Devices, Willian Harvey Research Institute, Queen Mary University of London London EC1A 7BE, UK.
Barts Health NHS Trust · GBQueen Mary University of London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recently, there has been growing interest in the early discharge strategy for low-risk patients who have undergone primary percutaneous coronary intervention (PCI) to treat ST-segment elevation myocardial infarction (STEMI). So far findings have suggested there are multiple advantages of shorter hospital stays, including that it could be a safe way to be more cost- and resource-efficient, reduce cases of hospital-acquired infection and boost patient satisfaction. However, there are remaining concerns surrounding safety, patient education, adequate follow-up and the generalisability of the findings from current studies which are mostly small-scale. By assessing the current research, we describe the advantages, disadvantages and challenges of early hospital discharge for STEMI and discuss the factors that determine if a patient can be considered low risk. If it is feasible to safely employ a strategy like this, the implications for healthcare systems worldwide could be extremely beneficial, particularly in lower-income economies and when we consider the detrimental impacts of the recent COVID-19 pandemic on healthcare systems.

Indexed as

early discharge strategylength of stayprimary PCISTEMI

Identifiers

PMID37213314
PMCPMC10193248
OpenAlexW4377219999

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.